Ambu gets US approval for new product

Ambu expects to launch Vivasight 2 on the US market during Q3 of its financial year 2020/2021

Photo: Andrew Kelly/REUTERS / X02844

The US Food and Drug Administration (FDA) has approved Ambu's product Vivasight 2 DLT, a ventilation tube with a camera, for single-use purposes.

The medtech company revealed the news in connection with its Q2 report released on Wednesday morning.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Orphazyme cuts guidance following FDA setback

Friday's disappointing rejection letter from the US FDA is affecting Orphazyme's guidance for 2021. Now, the biotech firm forecasts an operating deficit of DKK 670-700m, up from DKK 100-150m.

Further reading

Related articles

Latest news

See all jobs